Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Numinus Expands Natural Psychedelic Research with New Biosecurity License

Numinus Expands Natural Psychedelic Research with New Biosecurity License

  • Post published:March 14, 2022
  • Post category:Press Release
Read more about the article Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research

Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research

  • Post published:March 9, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

  • Post published:February 28, 2022
  • Post category:Press Release
Read more about the article Numinus Appoints New Bioscience Advisors to Advance IP Development

Numinus Appoints New Bioscience Advisors to Advance IP Development

  • Post published:February 1, 2022
  • Post category:Press Release
Read more about the article Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

  • Post published:January 27, 2022
  • Post category:Press Release
Read more about the article Nova Mentis and KGK Science Form Tactical Partnership

Nova Mentis and KGK Science Form Tactical Partnership

  • Post published:January 27, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. Graduates to the OTCQX Best Market

Numinus Wellness Inc. Graduates to the OTCQX Best Market

  • Post published:January 26, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. Reports Q1 2022 Results

Numinus Wellness Inc. Reports Q1 2022 Results

  • Post published:January 20, 2022
  • Post category:Press Release
Read more about the article Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

  • Post published:January 19, 2022
  • Post category:Press Release
Read more about the article Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

  • Post published:January 14, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More